Literature DB >> 15566804

Monoclonal antibodies to p24-core protein of HIV-1 mediate ADCC and inhibit virus spread in vitro.

R Grunow1, L Franke, J Hinkula, B Wahren, E M Fenyö, M Jondal, R von Baehr.   

Abstract

BACKGROUND: Certain antigens of the HIV-1, e.g., gp120-envelop proteins, can be expressed on the membrane of HIV-infected cells. Little is known about the membrane expression of other HIV-antigens and their interaction with specific antibodies.
OBJECTIVE: To develop murine monoclonal antibodies (mAbs) to the p24-core protein of HIV-1 and to characterise their binding sites and biological activities on HIV-infected T cells.
METHODS: Monoclonal antibodies were developed from mice hyperimmunised with a recombinant p24-core protein from HIV-1. Two mAbs were epitope-mapped on overlapping peptides and characterised for their reactivity with non-fixed HIV-infected T cells by immunofluorescence staining and flow cytometric analysis. Their biological activities were studied for antibody-dependent cellular cytotoxicity (ADCC) and suppression of viral spread in vitro.
RESULTS: The epitopes of two selected mAbs were located on the amino terminal region of p24 in the regions 147-152 aa and 178-187 aa, respectively. The antibodies were able to react with living HIV-1 infected cells. The expression of the antigens was time-dependent after the infection of certain cell lines by HIV-1. The mAbs mediated a strong HIV-1-specific ADCC and were able to delay the spread of HIV-1 for about 6 days in cell cultures.
CONCLUSIONS: Certain epitopes of the p24-core protein of HIV-1 can be expressed on living, HIV-infected T cells and are recognised by specific antibodies. Such antibodies can destroy infected cells by ADCC or delay the virus spread, and therefore, should be considered in immunisation strategies against HIV.

Entities:  

Year:  1995        PMID: 15566804     DOI: 10.1016/s0928-0197(94)00039-5

Source DB:  PubMed          Journal:  Clin Diagn Virol        ISSN: 0928-0197


  7 in total

1.  Viral control in chronic HIV-1 subtype C infection is associated with enrichment of p24 IgG1 with Fc effector activity.

Authors:  Amy W Chung; Jenniffer M Mabuka; Bongiwe Ndlovu; Anna Licht; Hannah Robinson; Yathisha Ramlakhan; Musie Ghebremichael; Tarylee Reddy; Philip J R Goulder; Bruce D Walker; Thumbi Ndung'u; Galit Alter
Journal:  AIDS       Date:  2018-06-19       Impact factor: 4.177

2.  Can HIV p24 be a suitable scaffold for presenting Env antigens?

Authors:  Luigi Buonaguro; Maria Tagliamonte; Maria Lina Tornesello; Franco M Buonaguro
Journal:  Clin Vaccine Immunol       Date:  2011-09-07

3.  HIV-specific CD4-induced Antibodies Mediate Broad and Potent Antibody-dependent Cellular Cytotoxicity Activity and Are Commonly Detected in Plasma From HIV-infected humans.

Authors:  Katherine L Williams; Valerie Cortez; Adam S Dingens; Johannes S Gach; Stephanie Rainwater; Julie F Weis; Xuemin Chen; Paul Spearman; Donald N Forthal; Julie Overbaugh
Journal:  EBioMedicine       Date:  2015-10       Impact factor: 8.143

Review 4.  Systems serology: profiling vaccine induced humoral immunity against HIV.

Authors:  Amy W Chung; Galit Alter
Journal:  Retrovirology       Date:  2017-12-21       Impact factor: 4.602

5.  Enhancing natural killer cell function with gp41-targeting bispecific antibodies to combat HIV infection.

Authors:  Nitya S Ramadoss; Nancy Q Zhao; Barbra A Richardson; Philip M Grant; Peter S Kim; Catherine A Blish
Journal:  AIDS       Date:  2020-07-15       Impact factor: 4.632

Review 6.  Review of Current Cell-Penetrating Antibody Developments for HIV-1 Therapy.

Authors:  Muhamad Alif Che Nordin; Sin-Yeang Teow
Journal:  Molecules       Date:  2018-02-06       Impact factor: 4.411

7.  Tracking the Trajectory of Functional Humoral Immune Responses Following Acute HIV Infection.

Authors:  Madeleine F Jennewein; Jennifer Mabuka; Cassidy L Papia; Carolyn M Boudreau; Krista L Dong; Margaret E Ackerman; Thumbi Ndung'u; Galit Alter
Journal:  Front Immunol       Date:  2020-08-07       Impact factor: 7.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.